Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by Mole101on Feb 04, 2021 1:38pm

178 Views

Post# 32471852

SEDI

New Balance
Recent filings
2021-02-0409:18 2021-02-02	$AGN	Williams, Mark Stephen 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+235,322vol	457,415
2021-02-0409:17 2021-02-02	$AGN	Williams, Mark Stephen 5 - Senior Officer of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-330,000vol	340,000
2021-02-0409:16 2021-02-02	$AGN	Levine, David 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+73,118vol	143,722
2021-02-0409:15 2021-02-02	$AGN	Levine, David 4 - Director of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-82,500 vol	85,000
2021-02-0409:14 2021-02-02	$AGN	Sadhra, Michael 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+252,611vol	606,667
2021-02-0409:13 2021-02-02	$AGN	Sadhra, Michael 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-330,000vol	340,000
2021-02-0409:11 2021-02-02	$AGN	Moreau, Christopher 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+283,989vol	1,452,777
2021-02-0409:10 2021-02-02	$AGN	Moreau, Christopher 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Rights RSUs 57 - Exercise of rights	-412,500vol	425,000